Novavax Inc. buy nvestor
Start price
23.11.24
/
50%
€8.16
Target price
23.11.25
€160.00
Performance (%)
4.44%
End price
07.12.24
€8.52
Summary
This prediction ended on 07.12.24 with a price of €8.52. With a performance of 4.44%, the BUY prediction by nvestor for Novavax Inc. closed with a slight gain. nvestor has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Novavax Inc. | -5.548% | -5.548% | -35.046% |
| iShares Core DAX® | 0.734% | -0.964% | 17.910% |
| iShares Nasdaq 100 | -2.686% | -2.409% | 4.267% |
| iShares Nikkei 225® | -2.261% | -4.038% | 10.420% |
| iShares S&P 500 | -1.346% | -1.510% | 1.615% |
According to nvestor what are the pros and cons of Novavax Inc. for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
Very positive Cash Flow expected
High Investments for future growth
Small challenges to pay loans and raise capital
Very capable Management
Very differentiated customer and product portfolio
Growths much faster than the competition
Sustainability is very important
Management is a major shareholder
Small Risks for its business
Market Leader or Top 3
Very small cyclical dependencies
Undervalued
Very high dividend yield expected
Very valuable balance sheet
Top Rating
ROE higher than 15% per year
Very good company culture
Leading role in innovation
Strong uniques
Cons
Comments by nvestor for this prediction
In the thread Novavax Inc. diskutieren
In the thread Trading Novavax Inc.
Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.
Stopped prediction by nvestor for Novavax Inc.
Novavax Inc.
Start price
Target price
Perf. (%)
€7.96
29.12.24
29.12.24
€79.00
29.12.25
29.12.25
8.49%
04.01.25
04.01.25
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
Novavax Inc.
Start price
Target price
Perf. (%)
€8.52
08.12.24
08.12.24
€168.00
08.12.25
08.12.25
-1.00%
21.12.24
21.12.24
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected